Endometrial Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are 18 years of age or older.
- People who are pre-menopausal (still having menstrual periods, not yet reached menopause).
- People who have been diagnosed via ultrasound with a non-cancerous growth in the muscle wall of the uterus.
- People who are experiencing abnormal uterine bleeding, such as unusually heavy periods or bleeding between periods.
- People who have their ultrasound images available in a digital format.
Who may not be able to join:
- People who do not wish to participate.
- People who are under 18 years of age.
- People who have gone through menopause.
- People whose uterine growth measures 10 mm (about 1 cm) or smaller.
- People whose ultrasound results suggest the uterine growth may be cancerous or potentially cancerous (confirm with trial site).
- People who have uterine fibroids but are not experiencing any symptoms.
- People with a personal history of cancerous or pre-cancerous conditions of the uterus, including certain rare uterine tumours, uterine cancer, abnormal uterine lining cells, or cervical cancer.
- People who have a known condition affecting their ovaries.
- People who are currently receiving treatment for any other type of cancer.
- People whose digital ultrasound images are unavailable or whose image quality is not clear enough to properly assess the uterine growth.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Daniela Romualdi, MD, Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phone: +393392996830
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
To observe modifications in the volume of the myometrial lesion during treatment with relugolix/estradiol/norethisterone; To observe the ultrasound features of myometrial lesions during treatment with relugolix/estradiol/norethisterone
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.